Global Cancer Genome Sequencing Market Growth (Status and Outlook) 2023-2029

Global Cancer Genome Sequencing Market Growth (Status and Outlook) 2023-2029

Cancer genome sequencing refers to a method used to identify the complete DNA or RNA sequence of cancer cells based on the sequencing of a single, homogeneous or heterogeneous group of tumor cells.

LPI (LP Information)' newest research report, the “Cancer Genome Sequencing Industry Forecast” looks at past sales and reviews total world Cancer Genome Sequencing sales in 2022, providing a comprehensive analysis by region and market sector of projected Cancer Genome Sequencing sales for 2023 through 2029. With Cancer Genome Sequencing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Genome Sequencing industry.

This Insight Report provides a comprehensive analysis of the global Cancer Genome Sequencing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Genome Sequencing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Genome Sequencing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Genome Sequencing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Genome Sequencing.

The global Cancer Genome Sequencing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

It is a laboratory technique that characterizes DNA or RNA sequences of primary tumor tissue, the tumor micro environment (such as stromal / fibroblast cells), adjacent or distal normal tissue, or metastatic tumor sites. This technique generates information related to identification of nucleotide bases (DNA or RNA), mutation status, copy number and sequence variants, as well as structural variations including fusion genes and chromosomal translocations.

This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Genome Sequencing market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Second Generation
Third Generation

Segmentation by application
Treatment
Research

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Agilent Technologies
GE Healthcare Life Sciences
Johnson & Johnson
LI-COR Biosciences
Abbott Laboratories
Beckman Coulter
Bayer
Hamilton Thorne Biosciences
Integrated DNA Technologies
Microchip Biotechnologies
Myriad Genetics
Commonwealth Biotechnologies
ZS Genetics
Pacific Biosciences

Please note: The report will take approximately 2 business days to prepare and deliver.